Does potassium citrate administration change the type and composition of encrusted material on Double-J stent compared to primary stone?


Journal

International urology and nephrology
ISSN: 1573-2584
Titre abrégé: Int Urol Nephrol
Pays: Netherlands
ID NLM: 0262521

Informations de publication

Date de publication:
Sep 2021
Historique:
received: 12 04 2021
accepted: 14 05 2021
pubmed: 30 5 2021
medline: 21 1 2022
entrez: 29 5 2021
Statut: ppublish

Résumé

To evaluate the effect of potassium citrate administration on the composition of encrusted material on the ureteral stent after Double-J insertion. We designed a randomized clinical trial for our study; 65 patients that underwent transurethral lithotripsy and Double-J stent insertion were included in the study after informed consent and divided into two groups. In the first group (33 patients) potassium citrate was prescribed after surgery till stent removal and the second group (32 patients) followed without prescribing this medication. After stent removal, encrusted materials on removed stents were analyzed then the type and composition of encrusted material compared with the primary stone that was removed. Our results revealed that the type and composition of primary stone and encrusted stone were similar in patients that do not receive potassium citrate (p-value of 0.073, 0.251 and 0.944 for calcium oxalate, uric acid, and calcium phosphate respectively). In patients that taking potassium citrate rate of calcium oxalate (p-value < 0.001) and uric acid (p-value < 0.001) material on encrusted stent significantly decreased compared with the non-intervention group. Results of this study revealed that taking of potassium citrate after ureteral stent insertion significantly decreases the formation of calcium oxalate and uric acid encrusted material on Double-J stent so it could be recommended for prevention of stent encrustation in patients that primary stone analysis are calcium oxalate and uric acid stone.

Identifiants

pubmed: 34050877
doi: 10.1007/s11255-021-02891-x
pii: 10.1007/s11255-021-02891-x
pmc: PMC8164059
doi:

Substances chimiques

Potassium Citrate EE90ONI6FF

Types de publication

Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

1797-1803

Informations de copyright

© 2021. The Author(s), under exclusive licence to Springer Nature B.V.

Références

Arch Ital Urol Androl. 2009 Sep;81(3):188-91
pubmed: 19911683
Urol Clin North Am. 2019 May;46(2):245-255
pubmed: 30961857
J Urol. 2011 Feb;185(2):542-7
pubmed: 21168868
Urology. 2001 Oct;58(4):526-31
pubmed: 11597531
Prog Urol. 2008 Apr;18(4):230-7
pubmed: 18501303
Rev Urol. 2010 Spring;12(2-3):e147-51
pubmed: 20811552
Urol J. 2018 Nov 17;15(6):323-328
pubmed: 30043389
Urology. 2015 Oct;86(4):703-6
pubmed: 26297602
Urology. 2003 Oct;62(4):622-6
pubmed: 14550429
J Urol. 2003 Mar;169(3):1065-9; discussion 1069
pubmed: 12576847
Am J Med. 2003 Jul;115(1):26-32
pubmed: 12867231
J Endourol. 2009 Sep;23(9):1437-42
pubmed: 19698053
J Urol. 1991 Dec;146(6):1487-91
pubmed: 1942324
J Biomed Mater Res B Appl Biomater. 2017 Nov;105(8):2244-2253
pubmed: 27459232
Aktuelle Urol. 2017 May;48(3):248-251
pubmed: 28486737
Transl Androl Urol. 2019 Sep;8(Suppl 4):S436-S441
pubmed: 31656749
Balkan Med J. 2017 Aug 4;34(4):301-307
pubmed: 28443570
Cent European J Urol. 2017;70(3):270-274
pubmed: 29104790
ASAIO Trans. 1989 Jul-Sep;35(3):495-8
pubmed: 2597516
Urolithiasis. 2016 Feb;44(1):57-63
pubmed: 26645868
Hinyokika Kiyo. 2003 Jun;49(6):307-10
pubmed: 12894725
Radiographics. 2002 Sep-Oct;22(5):1005-22
pubmed: 12235330
Medicina (Kaunas). 2019 Feb 26;55(3):
pubmed: 30813602
Curr Urol Rep. 2018 Apr 10;19(5):35
pubmed: 29637309
Urologiia. 2018 May;(2):40-45
pubmed: 29901293
Biofouling. 2019 Jan;35(1):117-127
pubmed: 30732463
J Endourol. 2012 Feb;26(2):178-82
pubmed: 22007916
Curr Urol. 2018 Mar;11(3):126-130
pubmed: 29692691
Eur Urol Focus. 2021 Jan;7(1):7-8
pubmed: 32917561
J Endourol. 2021 Jan;35(1):84-90
pubmed: 32799700
J Urol. 2000 Sep;164(3 Pt 1):648-50
pubmed: 10953117
Urol Int. 2002;69(2):136-40
pubmed: 12187045
J Urol. 1985 Jul;134(1):11-9
pubmed: 3892044

Auteurs

Abdolreza Mohammadi (A)

Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran.

Mohammad Mehdi Rakebi (MM)

Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran.

Maryam Gholamnezhad (M)

Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran.

Mahin Ahmadi Pishkuhi (M)

Pars Advanced and Minimally Invasive Medical Manners Research Center, Pars Hospital, Iran University of Medical Science, Tehran, Iran.

Seyed Mohammad Kazem Aghamir (SMK)

Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran. mkaghamir@tums.ac.ir.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH